Core Viewpoint - The company, Huace Testing, emphasizes the accuracy and completeness of its quarterly report, ensuring no false records or misleading statements are present [2][3]. Financial Data Summary - The quarterly report has not been audited [3][5]. - The company confirms that there are no adjustments or restatements required for previous accounting data [3]. - There have been changes in the company's equity due to reasons such as new share issuance and stock buybacks [3]. - The company does not have any non-recurring profit and loss items that meet the definition of non-recurring gains and losses [4]. Shareholder Information - The company has provided details on the total number of ordinary shareholders and the top ten shareholders' holdings [4]. - There are no changes in the top ten shareholders due to securities lending activities [4]. Other Important Matters - The company has indicated that there are no other significant matters to report in this quarterly update [4].

Core Viewpoint - The company, 华测检测, reported steady revenue growth for 2024 and Q1 2025, demonstrating resilience as a comprehensive testing institution [1][2]. Group 1: Financial Performance - In 2024, the company achieved revenue of 6.08 billion yuan, a year-on-year increase of 8.6%, and a net profit attributable to shareholders of 921 million yuan, up 1.2% [1]. - For Q1 2025, revenue reached 1.287 billion yuan, reflecting an 8.0% year-on-year growth, with a net profit of 136 million yuan, increasing by 2.8% [1]. - The non-recurring net profit for 2024 was 860 million yuan, a 9.8% increase year-on-year [1]. Group 2: Business Segments - Life Sciences segment (environmental and food testing) generated 2.84 billion yuan, a 13.75% increase, driven by new growth points in marine environment and agricultural testing [2]. - Industrial Testing segment reported revenue of 1.20 billion yuan, up 10.32%, with improved gross margins due to business upgrades [2]. - Consumer Products Testing segment saw revenue of 988 million yuan, a modest increase of 0.88%, impacted by reclassification in medical device product lines [2]. - Trade Assurance segment achieved 764 million yuan in revenue, a 9.19% increase, maintaining competitive advantages in niche markets [2]. - Pharmaceutical segment revenue declined by 14.71% to 287 million yuan, affected by regulatory actions, although the company is optimistic about future growth in CMC research and medical devices [2]. Group 3: Profitability Metrics - The non-recurring net profit margin for 2024 was 14.14%, an increase of 0.16 percentage points year-on-year [3]. - The overall gross margin for 2024 was 49.5%, up 1.42 percentage points, indicating strong competitive advantages [3]. - The company faced asset impairment losses of 34 million yuan and credit impairment losses of 85 million yuan in 2024, attributed to certain subsidiaries [3]. Group 4: Q1 2025 Performance - In Q1 2025, the non-recurring performance grew by 11.0%, with a non-recurring net profit margin increasing by 0.27 percentage points [4]. - The gross margin for Q1 2025 was 46.3%, up 0.99 percentage points, while the expense ratio decreased by 0.56 percentage points [4]. - The company has been actively pursuing acquisitions, including entities in Taiwan and Greece, to enhance its service offerings [4]. Group 5: Future Outlook - Revenue projections for 2025-2027 are 6.521 billion yuan, 7.191 billion yuan, and 7.921 billion yuan, with year-on-year growth rates of 7.18%, 10.28%, and 10.15% respectively [4]. - Expected net profits for the same period are 1.014 billion yuan, 1.143 billion yuan, and 1.287 billion yuan, with growth rates of 10.1%, 12.6%, and 12.7% respectively [4]. - The company maintains a PE valuation of 19.2x, 17.0x, and 15.1x for the years 2025, 2026, and 2027 [4].

Investment Rating - The investment rating for the company is "Buy" and it is maintained [7]. Core Views - The company has demonstrated resilient growth with a revenue increase of 8.6% year-on-year, reaching 6.08 billion yuan in 2024. The net profit attributable to shareholders rose by 1.2% to 0.921 billion yuan, while the non-recurring net profit increased by 9.8% to 0.860 billion yuan [2][6]. - In Q1 2025, the company achieved a revenue of 1.287 billion yuan, reflecting an 8.0% year-on-year growth, with a net profit of 0.136 billion yuan, up 2.8% [2][6]. Summary by Sections Financial Performance - For 2024, the company reported a total revenue of 60.8 billion yuan, with a year-on-year growth of 8.6%. The net profit attributable to shareholders was 9.21 billion yuan, a 1.2% increase, and the non-recurring net profit was 8.60 billion yuan, up 9.8% [2][6]. - In Q1 2025, the company recorded a revenue of 12.87 billion yuan, an 8.0% increase year-on-year, with a net profit of 1.36 billion yuan, reflecting a 2.8% growth [2][6]. Business Segments - The revenue from the Life Sciences segment (including environmental and food testing) was 2.84 billion yuan, a 13.75% increase. The Industrial Testing segment generated 1.20 billion yuan, up 10.32%. The Consumer Products Testing segment saw revenue of 0.988 billion yuan, a modest increase of 0.88%. The Trade Assurance segment achieved 0.764 billion yuan, a 9.19% growth. However, the Medical and Pharmaceutical segment experienced a decline of 14.71%, with revenue of 0.287 billion yuan [6][10]. Profitability Metrics - The company’s non-recurring net profit margin for 2024 was 14.14%, a slight increase of 0.16 percentage points. The overall gross margin improved to 49.5%, up 1.42 percentage points, indicating strong competitive advantages and internal control capabilities [10]. - In Q1 2025, the gross margin was 46.3%, reflecting a year-on-year increase of 0.99 percentage points, while the non-recurring net profit margin improved by 0.27 percentage points [10]. Future Outlook - The company forecasts revenues of 65.21 billion yuan, 71.91 billion yuan, and 79.21 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 7.18%, 10.28%, and 10.15%. The net profit attributable to shareholders is expected to reach 10.14 billion yuan, 11.43 billion yuan, and 12.87 billion yuan over the same period, with corresponding growth rates of 10.1%, 12.6%, and 12.7% [10].

Core Viewpoint - The company Huace Testing announced a cash dividend plan for the fiscal year 2024, proposing a distribution of 1 yuan per share (before tax), totaling approximately 167 million yuan, which represents 18.16% of its net profit [2]. Group 1: Dividend Distribution - The proposed cash dividend for 2024 is 1 yuan per share, with a total cash payout of 167 million yuan [2]. - This marks the 17th cumulative cash distribution since the company's listing [2]. - The dividend yield for 2024 is 0.78%, an increase from 0.55% in 2023 [2]. Group 2: Financial Performance - For the fiscal year 2024, the company reported total revenue of 6.084 billion yuan, reflecting a year-on-year growth of 8.55% [2]. - The net profit for the same period was 921 million yuan, showing a year-on-year increase of 1.19% [2]. - The basic earnings per share (EPS) is reported at 0.55 yuan, with a weighted average return on equity (ROE) of 14.07% [2]. Group 3: Market Activity - The stock experienced a net outflow of 26.28 million yuan in principal funds today, with a total net outflow of 53.89 million yuan over the past five days [3]. - The latest margin financing balance for the stock is 564 million yuan, which has increased by 45.23 million yuan, representing an 8.72% rise over the past five days [4]. Group 4: Industry Comparison - Among the 22 companies in the social services sector that announced their 2024 dividend plans, Huace Testing's cash payout ranks fifth, with the highest being 548 million yuan from Foreign Service Holdings [4]. - The cash payout of Huace Testing accounts for 18.16% of its net profit, which is relatively moderate compared to other companies in the sector [4].

Beijing Dehao International Certified PublicAccountants(Limited Liability Partnership) 华测检测认证集团股份有限公司 审计报告及财务报表 德皓审字[2025]00000808号 北 京 德 皓 国 际 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) 审计报告 华测检测认证集团股份有限公司 （2024年 1 月 1 日至 2024年 12月 31日止） | | 目 | 录 | 页 | 次 | | --- | --- | --- | --- | --- | | 一、 | 审计报告 | | 1-7 | | | 二、 | 已审财务报表 | | | | | | 合并资产负债表 | | 1-2 | | | | 合并利润表 | | 3 | | | | 合并现金流量表 | | 4 | | | | 合并股东权益变动表 | | 5-6 | | | | 母公司资产负债表 | | 7-8 | | | | 母公司利润表 | | 9 | | | | 母公司现金流量表 | | 10 | | | | 母公司股东权益变动表 | | 11-12 | | ...

华测检测认证集团股份有限公司 内部控制审计报告 德皓内字[2025]00000037 号 北 京 德 皓 国 际 会 计 师 事 务 所 (特殊普通合伙 ) Beijing Dehao International Certified Public Accountants (Limited Liability Partnership) 华测检测认证集团股份有限公司 内部控制审计报告 （截止 2024 年 12 月 31 日） 目 录 页 次 一、 内部控制审计报告 1-2 内 部 控 制 审 计 报 告 内部控制具有固有局限性，存在不能防止和发现错报的可能性。 此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策 和程序遵循的程度降低，根据内部控制审计结果推测未来内部控制的 有效性具有一定风险。 德皓内字[2025]00000037 号 华测检测认证集团股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了华测检测认证集团股份有限公司（以下简称华测 检测）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控 ...

华测检测认证集团股份有限公司 独立董事 2024 年度述职报告 本人曾繁礼，中国国籍，1964 年出生，农学学士，世界经济学研究生。1986 年至 1999 年历任深圳商检局科员,文锦渡副处长，文锦渡副局长、局长、党委书 记，深圳商检局认证处处长、书记，1999 年至 2001 年深圳检验检疫局食检处处 长、党委书记；2001 年至 2004 年任深圳检验局办公室主任、书记；2004 年至 2010 年任蛇口检验局局长、党组书记（副厅）；2010 年至 2013 年任皇岗检验局 (副厅级局)局长，党组书记；2013 年至 2015 年任深圳检验局副局长(副厅)，党 组成员；2015 年 8 月至 2019 年任深圳市怡亚通供应链股份有限公司任集团副总 裁、集团党委书记兼食品冷链平台总裁；兼任深圳市报关协会副会长，深圳市金 融商会副会长，深圳市食材行业协会创会会长等。2019 年 3 月至今任南海盛汇 新能源（广东）有限公司和深圳粤海盛汇国际贸易有限公司总裁。2019 年 12 月 2 日起担任公司独立董事。 2、独立性情况说明 经认真自查，任职期间，本人任职符合《上市公司独立董事管理办法》第六 条规定的独立性 ...

华测检测认证集团股份有限公司 独立董事 2024 年度述职报告 本人作为公司的独立董事，任职期间严格按照《公司法》《证券法》《上市 公司独立董事管理办法》《上市公司治理准则》《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》《公司章程》及《公司独立董事 制度》等法律法规、规范性文件的相关规定和要求，诚实、勤勉、独立履行职责， 积极关注和参与研究公司的发展，促进公司规范运作，充分发挥独立董事的作用， 现将 2024 年度履职情况报告如下： 一、独立董事基本情况 1、个人简历及兼职情况 本人程海晋，中国国籍，1971 年生，康奈尔大学工商管理硕士。曾在通用电 气、霍尼韦尔担任业务发展并购总监，并曾在法国巴黎银行投行部、中银香港、 辉瑞/法玛西亚制药、正大集团任职，现任上海濂盛技术服务有限公司总裁。本 人在不同国家及行业的股权并购、战投、混改、不良收购重整、投后管理、跨国 经营、内审风控等领域拥有丰富的国内和国际化经验。2020 年 9 月 7 日起担任 公司独立董事。 2、独立性情况说明 经认真自查，任职期间，本人任职符合《上市公司独立董事管理办法》第六 条规定的独立性要求，不存在影响独 ...

华测检测认证集团股份有限公司 2024 年监事会工作报告 2024 年公司监事会在全体监事的共同努力下，根据《公司法》《证券法》等 法律、法规及《公司章程》等规章制度的规定，本着对公司全体股东负责的精神， 认真履行了有关法律、法规赋予的职权，积极有效地开展工作，对公司依法运作 情况和公司董事、高级管理人员履行职责的情况进行监督，维护了公司及股东的 合法权益。现将 2024 年监事会主要工作情况汇报如下： （三）2024 年 8 月 9 日，召开了第六届监事会第十二次会议，审议通过了 《2024 年半年度报告全文及摘要》及《关于为子公司开具履约保函的议案》 （四）2024 年 10 月 24 日，召开了第六届监事会第十三次会议，审议通过 了《2024 年第三季度报告全文》《关于拟购买土地使用权并投资建设项目的议 案》。 （五）2024 年 11 月 25 日，召开了第六届监事会第十四次会议，审议通过 了《关于为子公司开具履约保函的议案》。 二、监事会对公司 2024 年度有关事项的核查意见 公司监事会根据《公司法》《证券法》《深圳证券交易所创业板股票上市规 则》《公司章程》的有关规定，认真履行监事会的职责，对公 ...

董 事 会 二〇二五年四月十八日 经核查独立董事程海晋先生、曾繁礼先生及刘志权先生的任职经历以及签署的相 关自查文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要 股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍 其进行独立客观判断的关系，不存在其他影响独立董事独立性的情况，符合《上市公司 独立董事管理办法》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公 司规范运作》中对独立董事独立性的相关要求。 华测检测认证集团股份有限公司 华测检测认证集团股份有限公司 董事会关于独立董事独立性自查情况的专项报告 华测检测认证集团股份有限公司（以下简称"公司"）董事会根据《上市公司独 立董事规则》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第2号——创业板上市公司规范运作》《公司章程》及《公司独立董事制 度》等相关法律法规、规章制度的规定，就公司在任独立董事程海晋先生、曾繁礼先 生及刘志权先生的独立性情况进行评估并出具如下专项意见： ...